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Abstract 
Background: Never before have clinical trials drawn as much public 
attention as those testing interventions for COVID-19. We aimed to 
describe the worldwide COVID-19 clinical research response and its 
evolution over the first 100 days of the pandemic. 
Methods: Descriptive analysis of planned, ongoing or completed trials 
by April 9, 2020 testing any intervention to treat or prevent COVID-19, 
systematically identified in trial registries, preprint servers, and 
literature databases. A survey was conducted of all trials to assess 
their recruitment status up to July 6, 2020. 
Results: Most of the 689 trials (overall target sample size 396,366) 
were small (median sample size 120; interquartile range [IQR] 60-300) 
but randomized (75.8%; n=522) and were often conducted in China 
(51.1%; n=352) or the USA (11%; n=76). 525 trials (76.2%) planned to 
include 155,571 hospitalized patients, and 25 (3.6%) planned to 
include 96,821 health-care workers. Treatments were evaluated in 607 
trials (88.1%), frequently antivirals (n=144) or antimalarials (n=112); 78 
trials (11.3%) focused on prevention, including 14 vaccine trials. No 
trial investigated social distancing. Interventions tested in 11 trials 
with >5,000 participants were also tested in 169 smaller trials (median 
sample size 273; IQR 90-700). Hydroxychloroquine alone was 
investigated in 110 trials. While 414 trials (60.0%) expected completion 
in 2020, only 35 trials (4.1%; 3,071 participants) were completed by July 
6. Of 112 trials with detailed recruitment information, 55 had recruited 
<20% of the targeted sample; 27 between 20-50%; and 30 over 50% 
(median 14.8% [IQR 2.0-62.0%]). 
Conclusions: The size and speed of the COVID-19 clinical trials agenda 
is unprecedented. However, most trials were small investigating a 
small fraction of treatment options. The feasibility of this research 
agenda is questionable, and many trials may end in futility, wasting 
research resources. Much better coordination is needed to respond to 
global health threats.
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Introduction
On December 31, 2019, the World Health Organization 
(WHO) China Country Office was informed of pneumonia 
cases of unknown etiology1; on January 30, 2020, the WHO 
declared coronavirus disease 2019 (COVID-19)2 a public health 
emergency and on March 11 a pandemic3. Radical public health 
measures, including quarantine, social distancing, school 
and workplace closures, and others have been implemented 
worldwide, affecting the lives of billions of people. The pan-
demic resulted in rapid generation and dissemination of stud-
ies and their results4. However, information on trials that are 
planned, ongoing, finished, or published are spread across trial 
registries, preprint servers, publication databases and other reposi-
tories. In June, 2020, the number of ongoing trials outweighed 
by far completed trials; however, no overview of COVID-19 
trials has followed up on actual enrolment in ongoing trials5–8.
We established the COVID-evidence platform (www.covid- 
evidence.org) to collect this information in a central database 
of COVID-19 trials testing any interventions for treatment or 
prevention. We used COVID-evidence to describe the worldwide 
clinical research response to COVID-19, its evolution over the 
first 100 days since the first cases were officially reported, and 
the expected feasibility and risk of waste of resources. We 
describe the trials’ characteristics, their place in the research 
landscape, and how they changed over time.
Methods
Data sources
COVID-evidence includes trials from international registries 
(ClinicalTrials.gov, WHO International Clinical Trials Regis-
try Platform [ICTRP]), preprint servers (medRxiv, bioRxiv), 
PubMed, the WHO COVID-19 literature database, and a listing 
of all trials with ethical approval in Switzerland9.
Identification and selection of trials
Our protocol and details on the search strategies and specific 
definitions used for COVID-evidence are available on the Open 
Science Framework (OSF)10. We searched the relevant data 
sources using peer-reviewed search strategies developed by infor-
mation specialists. Results from literature databases and preprint 
servers were pre-screened by a single reviewer who excluded 
unsuitable publications (e.g. opinion papers or observational, 
non-interventional studies). Cases with unclear eligibility 
were discussed by at least three reviewers until consensus was 
reached.
We included any planned, ongoing or completed trial that 
tested any intervention to treat or prevent COVID-19 in humans 
that was registered or published within the first 100 days of the 
COVID-19 outbreak, i.e. after the first cases reported to the 
WHO to 100 days later (January 1 to April 9, 2020). We 
considered as a trial any study prospectively assigning an 
intervention11. This included randomized and non-randomized, 
controlled or non-controlled trials regardless of language, 
geographical region, or setting. Epidemiological studies or studies 
of diagnostic test accuracy (without any health-related outcome) 
were excluded.
Data extraction
For each trial, we extracted dates of registration and publi-
cation, design characteristics and details of the population, 
intervention, comparison, outcomes, geographic region, fund-
ing and setting. We categorized drugs and biologicals according 
to major pharmacological classes and main clinical indications.
A team of 19 reviewers (including clinicians, clinical research-
ers, clinical pharmacologists, meta-researchers and systematic 
reviewers) either manually extracted information or verified infor-
mation that was obtained with automatic data scraping methods. 
All details on scraping, variable definitions and extraction/ 
verification procedures are available on OSF10,12. For all trials 
registered up to April 9, 2020, we extracted data through 
April 30. The status for each trial was updated on July 6, 2020 
(using ClinicalTrials.gov where possible; if not, we used the 
ICTRP; for trials originally registered in the Chinese Clinical 
Trial Registry available through ICTRP we used the former if it 
was more up to date).
When a trial had entries in different data sources, we gave 
first priority to publications, second to preprints, and third to 
registries (here, ClinicalTrials.gov was preferred).
Author requests on enrolment
From May 12 to July 3, 2020, we emailed the corresponding 
investigators of all trials, except discontinued ones, inquiring 
about their enrolment accrual. Replies were collected up to July 6, 
2020.
Statistical analyses
All analyses were descriptive and reported as percentages, 
medians (interquartile range, IQR) or means. We used Ninox 
(Ninox Software GmbH, Berlin, Germany; version 2.6), and 
R (version 3.6).
Results
We identified 689 trials registered or published over the pan-
demic’s first 100 days, testing interventions to treat or prevent 
COVID-19 (see Underlying data)12 with a total planned sam-
ple size of 396,366 participants. As of July 6, 2020, 19 trials 
(including 4,378 participants) had been completed and had pub-
lished results, and 16 were completed without available results 
(5,173 participants). Thirty (4.4%) were active but no longer 
recruiting (59,259 participants), 384 (55.7%) started recruiting 
(217,357 participants), 174 (25.3%) had not yet started (97,406 
participants), 50 (7.3%) were discontinued (12,048 participants), 
and 4 (0.6%) were terminated (577 participants). The status was 
unknown for 12 (1.7%; 168 participants).
General characteristics
The 689 trials’ median target sample size was 120 (IQR 60 to 
300; Table 1); 40.7% (n=280) planned to enroll fewer than 100 
participants, 8.3% (n=57) over 1,000, and 1.6% (n=11) over 
5,000 (see Underlying data)12. 75.8% (n=522) trials were ran-
domized and 59.2% (n=408) did not use blinding (Table 1). 
Randomized trials were on average three times larger than 
non-randomized trials (median sample size 150 vs. 50).
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Although few trials focused on health-care workers (3.6% 
[n=25]), they were larger: 96,821 planned health-care workers 
(median 700 [IQR 400 to 2,486]) versus 155,571 planned 
patients (median 100 [IQR 50 to 240]) for the inpatient trials 
(76.2% [n=525]) (Table 1). Overall, 46.4% of the trials intended 
to use mortality as a primary (n=98) or secondary outcome 
(n=369; Table 1). Out of the 525 inpatient trials, 55.6% (n=292) 
planned on reporting mortality as an outcome.
Interventions to treat COVID-19
Out of the 689 trials, 607 (88.1%) assessed treatment interven-
tions (187,209 planned patients); drugs were more frequent 
(349 trials [57.5%]), encompassing a vast range of substances. 
The two most common pharmacological classes were antiviral 
drugs (assessed in 144 trials; e.g. lopinavir/ritonavir [n=45]) 
and antimalarial drugs (112 trials; e.g. hydroxychloroquine 
[n=83]). There were 106 trials investigating traditional medi-
cine and 70 exploring highly diverse pharmaceuticals of various 
classes, e.g. bismuth potassium citrate, ebastine, pirfenidone, dipy-
ridamole and hydrogen peroxidase (Figure 1 and see Extended 
data)12. The comparators were predominantly standard of care 
or no intervention (47.1% [n=286]), placebo (17% [n=103]) or 
other interventions (18%; [n=109]) (Table 1).
Interventions to prevent COVID-19
Overall, 78 trials (11.3%) focused on prevention (205,841 planned 
participants), mainly prophylactic drug use (n=41), vaccines 
(n=14; 9 already started recruitment; see Extended data)12 and 
Figure 1. Number of trials assessing the different intervention categories.  Interventions for treatment assessed in more than 25 
trial: antiviral drugs were assessed in 144 trials; (e.g. lopinavir/ritonavir [n=45]), antimalarial drugs in 112 trials; (e.g. hydroxychloroquine 
[n=83]), monoclonal antibodies in 52 trials (e.g. tocilizumab [n=26]), traditional medicine in 106 trials, other drug intervention in 70 trials, 
nonspecific anti-inflammatory/immunosuppressive drugs in 42 trials (e.g. colchicine [n=4]), antibiotic/anti-parasitic drugs in 34 trials (e.g. 
azithromycin [n=28]), biologicals in 80 trials (e.g. convalescent plasma [n=27]), procedures in 28 trials (e.g. renal replacement therapy [n=4]), 
other non-drug interventions in 27 trials (e.g. physical activity). More information can be found in the Extended data12. The first column 
represents the proportion of all trials that were of the specified type. The second column represents the proportion of all trials registered 
that week that were of the specified type (i.e. within week, between trial types). The third column represents the distribution of when trials of 
this type were registered (i.e. within trial type, between week), and can be interpreted as either a percentage or count (not specified). A trial 
might assess more than one intervention category and detail for prevention and treatment trials are given in the extended data12.
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non-pharmaceutical interventions (n=10) (e.g. masks or the use 
of media and influencers in people’s compliance to hygienic 
practices). Four trials (0.6%) assessed interventions both for 
prevention and for treatment. No trial planned to assess ben-
efits or harms of implementing or de-implementing any social 
distancing or lockdown measures.
Time trends and global shift
The number of trials increased rapidly; on average 0.5 trials per 
day were registered in January, 8.1 in February, 8.4 in March, 
and 17.6 in April 2020.
Trials were conducted in 42 countries and through international 
collaborations (Table 1; see Extended data)12. Half were from 
China (51.1% [n=352]), which dominated initially (Figure 2); 
starting March 2020, more trials came from other countries. 
Trial characteristics were similar across the five most fre-
quent geographical locations (China, USA, France, Spain and 
international) contributing to 73.3% (n=505) of the global trial 
research (Table 1). Traditional medicine was assessed in 30.4% 
of trials from China (n=107) but rarely in other countries.
Larger trials were initiated later. In February, fewer than 8% of 
trials included more than 500 participants in contrast to 29.6% 
of trials in March (Figure 3). Later trials more often used blind-
ing, placebo and mortality as primary outcome (Figure 3). 
Participations of healthcare workers and healthy people also 
started later. When the proportion of trials from China decreased, 
so did trials assessing traditional medicine (from 46.9% to 
0.9%) while the proportion of trials assessing drugs rose (from 
38.1% to 77.2%). Antivirals came under investigation earlier 
than antimalarials (Figure 1).
Large trials
Out of the 689 trials, 6.7% (n=46) planned to enroll 1,000 to 
5,000 participants. Most were randomized (89.1% [n=41]), 
assessed drugs (80.4%; n=37), and many were not blinded (52.2% 
[n=24]). Five were cluster-randomized. The top three regions 
were the United States (21.7%; n=10), France (13% [n=6]) 
and international collaborations (10.9% [n=5]) (see Extended 
data)12.
Eleven (1.6%) trials, registered between February and April 
2020, planned to enroll over 5,000 participants (see Extended 
data)12. There were 10 randomized (one cluster RCT), eight not 
blinded and five conducted in multiple countries. These trials 
tested drugs (n=9), masks (n=1) and traditional medicine (n=1). 
Three trials are described as platform trials (i.e. WHO Solidar-
ity trial13, RECOVERY trial14 and CROWN-CORONATION 
trial15) and use an adaptive design.
Six drug interventions tested in these 11 larger trials (seven 
for treatment and four for prevention) were simultaneously 
investigated in at least 10 smaller trials (see Extended data)12. 
Overall, 169 trials (143 for treatment, 24 for prevention and 
two for treatment and prevention) with fewer than 5,000 par-
ticipants assessed at least one intervention that was also assessed 
in a larger trial (median sample size 273 [IQR 90 to 700]; 134 
had fewer than 1000 participants). For 107 of those (63.5%) the 
larger trial was registered before. For example, 106 trials with 
Figure 2. Cumulative number of registered trials over time (a) by continent, and (b) for countries with at least 10 registrations (excluding 
China). Four trials not shown were registered in 2019 or earlier, with a study design subsequently adapted to address COVID-19 (EUCTR2015-
002340-14-NL; NCT03680274; NCT03331445; and NCT03808922). For 18 trials the registration date was unknown.
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Figure 3. Proportion of trials stratified according to (a) sample size, (b) type of participants, (c) type of control, (d) type of blinding, 
(e) purpose of the trial, and (f) use of mortality as outcome. The first column represents the proportion of all trials that were of the specified 
type. The second column represents the proportion of all trials registered that week that were of the specified type (i.e. within week, 
between trial types). The third column represents the distribution of when trials of this type were registered (i.e. within trial type, between 
week), and can be interpreted as either a percentage or count (not specified).
fewer than 5,000 participants tested hydroxychloroquine and 
88 of them (83%) were registered after the first large trial test-
ing this drug and 83 (77.6%) assessed hydroxychloroquine as 
treatment (Figure 4; see Extended data)12. These 106 trials had 
a median sample size of 334, but cumulatively, they planned to 
enroll as many patients as the four larger trials testing 
hydroxychloroquine (76,617 vs 77,000).
Outlook
By the end of 2020, 414 trials (60.1%) with a total of 160,107 
planned participants were expected to be completed (i.e. last 
patient, last visit), including 240 drug trials (97,846 partici-
pants) and 22 over-1,000 participants trials and five over-5,000 
participants trials. For vaccines, five trials expected completion 
in 2020, five in 2021 and another four between 2022 and 2024 
(see Extended data)12. However, of the 270 trials that planned 
to start recruiting by the end of February, 190 started (70.4%), 
but 80 had not (as of July 6, 2020) (see Extended data)12.
By July 6, 2020, we received enrolment information for 112 
out of the 604 trials listed as planned or ongoing (18.7%). 
Of the 112 trials, 16 had not started recruiting although their 
start dates were overdue; one was discontinued. Among the 112 
trials, 55 had recruited fewer than 20% of the target sam-
ple size, 27 between 20-50%, and 30 more than 50% (median 
recruitment 14.8% [IQR 2.0 to 62.0%]; median duration of 
recruitment 72 days [IQR 53.5 to 83 days])). Median recruit-
ment was similar in treatment and prevention trials (15.9% (IQR 
2 to 61.1%] vs 14.8% [IQR 4.3 to 62.5%]). For 19 trials, 
investigators mentioned difficulties in recruitment due to a 
fortunate decrease in the number of COVID-19 cases.
Discussion
The global clinical research community has mounted a mas-
sive, unprecedented volume of research in response to the 
COVID-19 pandemic. Almost 700 trials within 100 days 
planned to include almost 400,000 participants globally. Many 
Page 10 of 18
F1000Research 2020, 9:1193 Last updated: 06 OCT 2020
Figure 4. The 110 Trials assessing hydroxychloroquine for COVID-19 registered in the first 100 days of the pandemic. The dashed 
lines represent the registration of the four trials planning to enroll over 5,000 participants; two were registered on April 2, 2020. Out of the 
four trials planning on enrolling over 5,000 participants, two assessed hydroxychloroquine for treatment and two for prevention. Out of the 
106 smaller trials, 83 assessed hydroxychloroquine for treatment, 22 for prevention and one for both treatment and prevention
treatments were planned for investigation, mostly drugs, often 
antivirals, and sometimes substances that may seem rather 
unexpected for an infectious disease (e.g. colchicine or dipyri-
damole) reflecting the huge heterogeneity of disease manifesta-
tions and therapeutic targets16. Few trials focused on prevention, 
but some were very large and focused on healthcare workers 
(i.e. 24.4% of planned trial participants are healthcare work-
ers). Trials from China dominated the research agenda before 
research activities followed the spread of COVID-19 through-
out the world. Most trials were planned as randomized, 
clearly demonstrating that such designs are possible within a 
pandemic17 and within a very short time, unlike the 2014–
2015 Ebola outbreak where only a few therapeutic trials had a 
randomized design, and none started within 100 days17.
The emergence of 689 trials in a 100-day period is unparal-
leled. Between 250 to 342 HIV/AIDS trials are registered 
per year on ClinicalTrials.gov18 and only three were registered for 
Middle East respiratory syndrome (MERS) coronavirus during 
2007–201718. While efforts being put into clinical trials were 
initially welcome, the vast majority of COVID-19 trials are at 
risk of being abandoned if they cannot recruit enough patients or 
if other trials on the same treatment provide conclusive results 
(favorable or unfavorable).
Thomas Chalmers highlighted in 1977 the need to ‘Randomize 
the first patient’19, and a reassuring 75% of trials are indeed 
randomized. However, we identified areas of concern. Most tri-
als are not blinded, and even if placebos may be not available 
in such short time, blinding of outcome collection would be 
preferable. Blinding may not be required for mortality outcomes; 
however, it was rarely a primary outcome. Half of the trials 
include fewer than 120 patients and many small trials were ini-
tiated after public registration of very large trials addressing 
similar questions. They may have some heterogeneity in design 
that might be desirable or focus on specific situations, for 
example early Phase 1 vaccine trials, but it seems unlikely that 
such small trials would add meaningfully to the overall evidence. 
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The extensive worldwide discussions about limited evidence 
from small trials reflect the substantial uncertainty patients and 
decision-makers face about the merits of popular interventions, 
such as hydroxychloroquine20.
For hydroxychloroquine, over 100 smaller studies with over 
76,000 patients were planned in the first 100 days to investigate 
this single therapeutic option out of many potential options. This 
case, possibly fueled by media attention relayed by decision- 
makers and politicians, highlights the urgent need for early 
evidence-based research and priority setting. Such prolifera-
tion may reflect best intentions of clinical researchers to actively 
contribute to evidence generation and inform timely treat-
ments locally instead of awaiting published evidence or using 
experimental treatments outside of clinical trials. It may 
also indicate a lack of research structures allowing them to 
contribute to larger, synergistic trials. With the emergence of 
results, the entire agenda may shift. Many hydroxychloroquine 
and chloroquine trials’ enrolment was temporally halted due 
to harmful effects in an observational study21, the publication of 
which was subsequently retracted22. However, the release of the 
randomized RECOVERY trial results showing no benefit (in fact, 
a trend for increased mortality)23 with hydroxychloroquine and 
another “negative” trial on hydroxychloroquine-prophylaxis24 
created uncertainties about the feasibility (i.e. inability to 
recruit planned sample sizes) or futility (i.e. inability to dem-
onstrate treatment effects) of all the ongoing and planned 
hydroxychloroquine trials.
There are excellent examples of how efficient structures 
allow for rapid response to evidence needs, such as the UK 
RECOVERY trial25. Strongly endorsed and prioritized by authori-
ties and medical representatives26, it is running as streamlined 
pragmatic platform trial in over 176 hospitals, randomizing over 
12,000 patients in just over four months14. It has already pro-
vided evidence on the lack of benefit for hydroxychloroquine23 
and lopinavir/ritonavir27, and a reduction of mortality with 
dexamethasone28 (still awaiting results for azithromycin, tocili-
zumab and convalescent plasma). Such key trials have had 
major impact on decision-makers such as the FDA revoking 
the Emergency Use Authorization of hydroxychloroquine29 on 
June 15.
Conversely, we found other large trials with major recruitment 
difficulties. The DisCoVeRy trial, for example, was designed 
as an adaptive trial of 3200 patients, running in 35 countries. 
However, while DisCoVeRy recruited 758 patients in France, 
only one was recruited in the rest of Europe30, as of June 
17, 2020.
The lack of coordination in the research response created sub-
stantial research waste, exposed many patients to unnecessary 
risks, and harms medical progress by creating competition 
among trials investigating similarly promising therapeutic 
alternatives31–33. However, in absence of such desirable research 
synergies, all these scattered activities can and should be 
bundled to contribute to rapid evidence generation in living 
meta-analyses. The COVID-evidence database provides a unique 
opportunity to surveil the planned, ongoing and completed tri-
als that can then be synthesized – it would only need systematic 
sharing of trial data.
As many countries are facing restrictions of movement and 
lifestyle at various severity levels, affecting the physical and 
mental health of billions of people, it is remarkable that not a 
single trial was initially planned to evaluate these measures. 
While the lack of controlled experiments evaluating their 
implementation may not be unexpected (given the initial 
urgency, ethical considerations, and organizational challenges), 
it would now be highly desirable that the de-implementation 
or re-implementation be subject to systematic evaluation in 
high-quality trials. The diverse options to ease or reinforce 
lockdown would be amenable to randomization, such as 
alternative time points or extents of re-opening schools or 
kindergartens, of ways to protect elderly in nursing homes, of 
home office programs, or of contact restrictions. Such evidence 
would be critical to inform future pandemics or the management 
of possible second waves of COVID-19, yet it was not on the 
initial agenda.
Limitations
Several limitations merit attention. First, unclear reporting 
in registries might have introduced inaccurate results. Some 
ambiguously reported items required discussion among several 
reviewers but were resolved to the best of our ability. Second, 
we rarely identified protocols or manuscripts, precluding more 
detailed analyses of trial designs. Third, some control groups 
receiving “standard of care” interventions were not clearly 
described, likely some of these included interventions that were 
or are still under investigation in other trials. Fourth, we may 
have missed a few cases of duplicate entries across registries or 
of multiple national parts of an international trial, thus slightly 
overestimating the number of trials but not affecting the overall 
interpretation. Fifth, we arbitrarily selected a period of the 
first 100 days, which is traditionally used to benchmark early 
outcomes of policies or presidencies. Finally, we do not 
assess the actual research output from all these early trials. This 
unprecedentedly fast-moving research body is scattered across 
data sources and registries without uniform updates. More 
definitive answers will require more time, but our results 
allow for the diagnosis of “system cracks”34 that may become 
symptomatic in this pandemic, such as infrastructure limitations, 
and also identify best practices.
Conclusion
The incredible volume and speed of trial research observed 
in the first 100 days of the COVID-19 pandemic should not 
hide the fact that in its early days the global clinical trial research 
agenda lacked clear coordination, efficiency and exploita-
tion of synergies. There are excellent examples of very large 
trials implemented with impressive efficiency, likely providing 
the clearest evidence. However, early coordination and a unified 
approach are needed - otherwise futility and waste of resources 
may be prominent features of such an ambitious research 
agenda.
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Data availability
Underlying data
All data underlying the results are available as part of the article 
and no additional source data are required.
Extended data
Open Science Framework: COVID-evidence: a living data-
base of trials on interventions for COVID-19 / The worldwide 
clinical trial research response to the COVID-19 pandemic - the 
first 100 days; https://doi.org/10.17605/OSF.IO/PJEM312.
-    2020-07-06-Dataset_manuscript.xlsx. (Raw trial metadata.)
-    2020-06-03_COVe_Procedures_Variables_manuscript.pdf. 
(Procedures for screening and extracting data.)
-    2020-09-08-Extended_data_Manuscript.docx. (Extended data 
Figures 1–5 and Tables 1–5.)
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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The manuscript addresses an important topic, and was an interesting and relatively easy read. 
Thanks for that!  
 
I have only managed to find one issue of some substance to comment on, and one very minor 
thing. 
 
In the Discussion section you raise the argument that lack of blinding is a problem, especially 
since many trials don’t have mortality as a main outcome. This is in line with the general 
understanding that “subjective” outcomes, i.e. outcomes based on some degree of judgement, are 
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“Strongly endorsed and prioritized by authorities and medical representatives, it is running as 
streamlined pragmatic platform trial in over 176 hospitals, randomizing over 12,000 patients in 
just over four months”. 
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